Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Entheon Biomedical Corp (OP: ENTBF )

0.2260 +0.0329 (+17.04%)
Streaming Delayed Price Updated: 3:18 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 157
Open 0.2260
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1931
Today's Range 0.2260 - 0.2260
52wk Range 0.0225 - 0.2880
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development Program
Via Investor Brand Network

Performance

YTD
+86.16%
+86.16%
1 Month
-21.53%
-21.53%
3 Month
+125.10%
+125.10%
6 Month
+179.01%
+179.01%
1 Year
+114.02%
+114.02%

More News

Read More
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004
Via Investor Brand Network
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Via Benzinga
Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin
Via Benzinga
Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
Via Benzinga
Entheon Biomedical Announces Non-Brokered Private Placement Financing
Via Benzinga
Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
Via Benzinga
Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins
Via Benzinga
Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient
Via Benzinga
Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments
Via Benzinga
Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) Featured in Virtual Coverage of Benzinga’s Small Cap Conference
Via Investor Brand Network
Compass Pathways 2.0: A New Rally In Psychedelic Stocks?
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials
Via Newsfile
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Via Benzinga
Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics
Via Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Via Benzinga
Clinical Director of Imperial College's Center for Psychedelic Research Joins Entheon Advisory Board
Via Newsfile
Entheon Biomedical Corp. Announces DTC Eligibility
Via Newsfile
CORRECTION FROM SOURCE: BTV Examines the Rapidly Expanding Psychedelics Market
Via Newsfile
BTV Examines the Rapidly Expanding Psychedelics Market
Via Newsfile
Entheon Biomedical Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine
Via Newsfile
Exposures Product Safety
Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected
Via Benzinga
Entheon Biomedical Corp. Strengthens Its Psychedelic-Assisted Protocols Through Acquisition Of Lobo Genetics
Via Benzinga
Entheon Biomedical Corp. Acquires Lobo Genetics Inc.
Via Newsfile
Topics Cannabis
Exposures Cannabis
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.